This statistic shows the estimated market value of biosimilars in Italy between 2018 and 2022, by type of originator. According to data, the biosimilar produced from Adalimumab is expected to generate a market value of million euros between 2018 and 2022, while the market value of Trastuzumab biosimilar is forecasted to reach million euros, in the same period.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆÆ½â°æ can support your business.
IQVIA. (July 3, 2018). Estimated market value of biosimilars in Italy between 2018 and 2022, by type of originator* [Graph]. In ÌÇÐÄÆÆ½â°æ. Retrieved August 01, 2026, from /statistics/877593/estimated-market-value-of-biosimilars-by-type-in-italy/
IQVIA. "Estimated market value of biosimilars in Italy between 2018 and 2022, by type of originator*." Chart. July 3, 2018. ÌÇÐÄÆÆ½â°æ. Accessed August 01, 2026. /statistics/877593/estimated-market-value-of-biosimilars-by-type-in-italy/
IQVIA. (2018). Estimated market value of biosimilars in Italy between 2018 and 2022, by type of originator*. ÌÇÐÄÆÆ½â°æ. ÌÇÐÄÆÆ½â°æ Inc.. Accessed: August 01, 2026. /statistics/877593/estimated-market-value-of-biosimilars-by-type-in-italy/
IQVIA. "Estimated Market Value of Biosimilars in Italy between 2018 and 2022, by Type of Originator*." ÌÇÐÄÆÆ½â°æ, ÌÇÐÄÆÆ½â°æ Inc., 3 Jul 2018, /statistics/877593/estimated-market-value-of-biosimilars-by-type-in-italy/
IQVIA, Estimated market value of biosimilars in Italy between 2018 and 2022, by type of originator* ÌÇÐÄÆÆ½â°æ, /statistics/877593/estimated-market-value-of-biosimilars-by-type-in-italy/ (last visited August 01, 2026)
Estimated market value of biosimilars in Italy between 2018 and 2022, by type of originator* [Graph], IQVIA, July 3, 2018. [Online]. Available: /statistics/877593/estimated-market-value-of-biosimilars-by-type-in-italy/